Schonfeld Strategic Advisors’s Entera Bio ENTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$61.3K	Sell	55,223 -541,362	-91%	-$760K	﹤0.01%	1944
2025 Q4	$1.16M	Buy	596,585 +29,629	+5%	+$69.5K	0.01%	1075
2025 Q3	$1.09M	Sell	566,956 -37,566	-6%	-$71.9K	0.01%	1321
2025 Q2	$1.15M	Buy	604,522 +5,366	+0.9%	+$10.6K	0.01%	1242
2025 Q1	$1.02M	Sell	599,156 -33,155	-5%	-$72.1K	0.01%	1282
2024 Q4	$1.34M	Sell	632,311 -16,289	-3%	-$30.4K	0.01%	996
2024 Q3	$1.23M	Sell	648,600 -23,158	-3%	-$41.1K	0.01%	1091
2024 Q2	$1.24M	Buy	+671,758	New	+$1.47M	0.01%	1112

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SEIA

Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Schonfeld Strategic Advisors's ENTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Entera Bio (ENTX) stake by 91% in Q1 2026, selling an estimated $760K and leaving 55,223 shares worth $61.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1944.

Schonfeld Strategic Advisors first reported a position in ENTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.34M in Q4 2024. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

Schonfeld Strategic Advisors held 55,223 shares of Entera Bio worth $61.3K as of Q1 2026.
Schonfeld Strategic Advisors sold 541,362 Entera Bio shares in Q1 2026, an estimated $760K.
Entera Bio made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1944 holding.
Schonfeld Strategic Advisors first reported a position in Entera Bio in Q2 2024 and has held it in 8 quarters since.
Schonfeld Strategic Advisors's Entera Bio position peaked at $1.34M in Q4 2024.
26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.